Life Care News
A Hope Of True Information

UPDATE — Actuate Therapeutics Announces Poster


CHICAGO and FORT WORTH, Texas, April 10, 2023 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today three poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.

The abstracts are currently available on the AACR meeting website. The posters will be available online at following the presentations.

Poster Presentation Details:

Abstract 3857 / 7: Exploring mechanisms of resistance to elraglusib in pancreatic cancer PDX models
Date/Time: Tuesday, April 18, 2023, 9:00 AM – 12:30 PM
Session: Drug Resistance in Molecular Targeted Therapies 3
Presenter: Taylor Weiskittel, Mayo Clinic, Rochester, MN
Location: Poster Section 15 Abstract CT222 / 12: Multimodal mechanism of action of the GSK-3 inhibitor 9-ING-41 (elraglusib) includes an immunomodulatory component: preliminary results from the 1801 phase 1/2 trial
Date/Time: Tuesday, April 18, 2023, 9:00 AM – 12:30 PM
Session: Phase II Clinical Trials 2
Presenter: Dr. Benedito Carneiro, Brown University/Lifespan, Providence, RI
Location: Poster Section 47 Abstract 5355/4: Elraglusib response prediction and mechanistic discovery using iterative machine learning
Date/Time: Tuesday, April 18, 2023, 1:30 PM – 5:00 PM
Session: Artificial Intelligence and Machine/Deep Learning 1
Presenter: Joseph McDermott, Lantern Pharma Inc., Dallas TX
Location: Poster Section 31

- Advertisement -

About Actuate Therapeutics, Inc.
Actuate is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for high impact cancers and inflammatory diseases. Actuate’s lead drug, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy. Elraglusib is also emerging as a mediator of anti-tumor immunity through the inhibition of multiple immune checkpoints and the regulation of immune cell function. For additional information, please visit the Company’s website at

Public Relations Dept.,
Actuate Therapeutics, Inc.
+1 (847) 986-4190 

Get real time updates directly on you device, subscribe now.